Significance of Liquid Biopsy Containing Circulating Tumor DNA (ctDNA) Analysis for Evaluation and Management of Metastatic Cancer
Journal Title: Diseases & Research - Year 2023, Vol 3, Issue 1
Abstract
According to the GLOBOCAN 2020 data from WHO, nearly 10 million deaths took place due to cancer thus, cancer became a leading cause of death all over the world. The most common cancer are breast cancer, lung cancer, colon cancer, prostate cancer, and pancreatic cancer. In the last few decades, Tissue Biopsy was considered the major approach to finding a confirmed diagnosis of particular cancer but due to the invasive process, it has become difficult for the clinician to ask for frequent tissue biopsies for the monitoring targeted treatment of the patients and thus clinicians generally assume the potency of the drugs without doing any biopsy analysis and thus there is an increase in the mortality of cancer patients. However, the liquid biopsy technique has changed this protocol of such treatment and greatly revolutionized the field of Clinical Oncology. Liquid biopsy ensures better-targeted treatment and many times help to give a complete cure. Liquid Biopsy is a non-invasive standard procedure to identify and prognose the tumor markers from circulating blood samples. It also offers the ease of sampling continuous screening, monitoring devices, therapeutic regimens, etc. Liquid Biopsy is composed of several components such as Circulating Tumor Cells (CTCs), free Circulating Tumor DNA (ctDNA), exosomes, vesicles, and platelets. The liquid biopsy includes body fluids such as blood, saliva, plasma, cerebrospinal fluid, and urine. Circulating Tumor DNA (ctDNA) in the blood sample of metastatic cancer patients has become the most critical technology to evaluate the progression of metastasis and give a precise treatment for many cancers. ctDNA analysis provides insight into the molecular profiling and biological characteristics of several tumors. This review is mainly aimed at highlighting the important technological development in ctDNA analysis and also to provide the significance of it in monitoring metastatic cancers and providing the best treatment to cure cancer.
Authors and Affiliations
Mansi Gupta, Pravin Potdar
Keywords
Related Articles
- EP ID EP740142
- DOI 10.54457/DR.202301003
- Views 55
- Downloads 0
Clinical Study on Flumatinib Mesylate Combined with Chemotherapy Followed by Autologous Hematopoietic Cell Transplantation in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Objective To investigate the clinical efficacy and safety of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) patients treated with second-generation tyrosine kinase inhibitor (TKI) flumatinib mesyl...
Review on Tumour Microenvironment Cell Types Associated with Metastatic Cancer
The Tumour microenvironment (TME) is a highly dynamic and perpetually altering entity of cancer development, progression, invasion, and dissemination. TME is interspersed with cellular components such as immune cells, bl...
Utilization of Traditional Chinese Medicine Monomers in the Therapeutic Management of Enteritis-Associated Inflammation
Chronic enteritis with inflammatory characteristics is a persistent and recurring inflammation of the intestinal tract, resulting from a myriad of causative factors. Currently, the customary pharmacological treatments fo...
Updating CAR-T Cell Immunotherapy for Liquid and Solid Tumor
According to the GLOBOCAN 2020 report, there is still a 50% mortality rate observed in cancer patients despite the availability of various innovative cancer therapies. This highlights the need for specific therapies that...
Multiparameter Flow Cytometry: An Important Auxiliary Tool for The Diagnosis and Differential Diagnosis of Myelodysplastic Neoplasms
Multiparameter flow cytometry (MFC) shows promise in the diagnosis and differential diagnosis of myelodysplastic neoplasms (MDS). By identifying abnormal immunophenotypes of different cell lineages in bone marrow (BM) ce...